Deleterious POT1 mutations are present in approximately 3% of all tumors, with a higher prevalence in angiosarcomas, non-small-cell lung cancers, and cutaneous squamous cell carcinomas and melanomas. Here, POT1 is linked to non-small cell lung carcinoma.